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Abstract: The availability of blood-based diagnostic testing using a non-invasive technique holds
promise for real-time monitoring of disease progression and treatment selection. Circulating tumor
cells (CTCs) have been used as a prognostic biomarker for the metastatic breast cancer (MBC).
The molecular characterization of CTCs is fundamental to the phenotypic identification of malignant
cells and description of the relevant genetic alterations that may change according to disease
progression and therapy resistance. However, the molecular characterization of CTCs remains
a challenge because of the rarity and heterogeneity of CTCs and technological difficulties in the
enrichment, isolation and molecular characterization of CTCs. In this pilot study, we evaluated
circulating tumor associated cells in one blood draw by size exclusion technology and cytological
analysis. Among 30 prospectively enrolled MBC patients, CTCs, circulating tumor cell clusters (CTC
clusters), CTCs of epithelial–mesenchymal transition (EMT) and cancer associated macrophage-like
cells (CAMLs) were detected and analyzed. For molecular characterization of CTCs, size-exclusion
method for CTC enrichment was tested in combination with DEPArray™ technology, which allows
the recovery of single CTCs or pools of CTCs as a pure CTC sample for mutation analysis. Genomic
mutations of TP53 and ESR1were analyzed by targeted sequencing on isolated 7 CTCs from a patient
with MBC. The results of genomic analysis showed heterozygous TP53 R248Wmutation from one
single CTC and pools of three CTCs, and homozygous TP53R248Wmutation from one single CTC and
pools of two CTCs. Wild-type ESR1 was detected in the same isolated CTCs. The results of this study
reveal that size-exclusion method can be used to enrich and identify circulating tumor associated
cells, and enriched CTCs were characterized for genetic alterations in MBC patients, respectively.
Keywords: metastatic breast cancer (MBC); circulating tumor associated cells; circulating tumor
cells (CTCs); circulating tumor cell clusters (CTC clusters); epithelial–mesenchymal transition (EMT);
cancer associated macrophage-like cells (CAMLs); size-exclusion technology
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1. Introduction
Breast cancer is the most common cancer in women and metastasis is the major cause of the
mortality of patients [1]. The treatment for aggressive metastatic breast cancer (MBC) remains
challenging as the intrinsic clinical subtypes, biological features of the metastases, and tumor
heterogeneity including circulating tumor cells (CTCs) all contribute to the resistance to current
standard strategies [2]. Current treatments mainly rely on expression profiles of the primary tumor
or metastatic tumor biopsy. However, the expression profiles may change during or after adjuvant
treatments or targeted therapies. A real-time tumor assay using a liquid biopsy that focuses on
the analysis of CTCs and circulating tumor DNA (ctDNA) has been actively investigated as new
therapeutic targets and drug resistance mechanisms in cancer patients [3,4]. Blood-based testing using
a non-invasive and complementary approach has the potential to enhance therapeutic efficacy and
improve the outcome of MBC patients.
Circulating tumor cells are rare cells that are shed into bloodstream from primary or metastatic
tumors with the potential to initiate tumor metastasis in distant organs [5,6]. The enumeration
of CTCs can provide consistent prognostic values in MBC patients [7,8]. The semi-automated
CellSearch® platform (Janssen Diagnostics, Raritan, NJ, USA) is the only FDA-approved platform
for CTC detection and enumeration based on the expression of epithelial cell adhesion molecule
(EpCAM) [7–10]. EpCAM-based assay is unable to detect CTCs with low or absent EpCAM expression
and other circulating tumor associated cells, including stem cell-like tumor cells and CTCs undergoing
epithelial–mesenchymal transition (EMT), which were identified by stem cell and EMT markers
in early and metastatic breast cancer patients [11–13]; and cancer associated macrophage-like cells
(CAMLs), which are specialized phagocytic myeloid cells found in the peripheral blood of patients
with solid tumors including breast cancer, but not in healthy individuals [14]. CellSearch and other
EpCAM-based assays may miss the detection of these cells.
Due to the limitation of EpCAM-based capture assays for the detection of various circulating
tumor associated cells, many other technologies have been developed including size-execution
enrichment devices [15]. ScreenCell® technology is a range of specific devices and has been validated
for the detection and molecular analysis of CTCs in several other solid tumors including prostate,
pancreatic cancer, renal, colon, and lung [16–21]. Without surface-marker selection, size-execution
method allows the capture of all types of circulating tumor associated cells in one blood draw and
exploring the phenotypic and genetic heterogeneity of these cells.
Molecular characterization of CTCs is important to confirm their malignant origin and to identify
the genomic abnormalities that may be undetectable or different from the primary tumor during
disease progression and therapy resistance in order to achieve individual patient management and
treatment. CTCs are rare and very heterogeneous populations of tumorigenic cancer cells in the
blood of patients with metastatic cancer, which makes their isolation and characterization challenging.
Isolation of pure CTCs from pre-enriched blood samples is a key step for exploring accurate genomic
analysis. The DEPArray™ technology (Silicon Biosystems, San Diego, CA, USA) is the ideal system
to collect pure CTCs for further molecular characterization. Recent studies showed a workflow that
enables isolation and molecular characterization at single CTCs, which highlight the potential clinical
utility for diagnostic molecular profiling in precision medicine [22–24]. The CTCs have been enriched
from large population of red blood cells (RBCs) and white blood cells (WBCs) before single-cell sorting
processing with DEPArray™ technology. CellSearch enrichment is the current commonly used method
for DEPArray single-cell sorting.
In this pilot study, we aim to detect and validate circulating tumor associated cells including
CTCs, CTC clusters, EMT CTCs, and CAMLs in one blood draw for MBC patients. In addition, we
aim to explore the applicability of a protocol for the molecular characterization of pure CTCs by size
exclusion enrichment method followed by single-cell sorting using the DEPArray™ in one patient
blood sample. We target to analyze TP53 and ESR1mutations based on the mutations data found in
the corresponding patient￿s tumor tissue sample.
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2. Results
2.1. Detection of Circulating Tumor Associated Cells
Thirty patient blood samples were processed for the evaluation of CTCs and CTC clusters in
this study. The morphological phenotypes of CTCs and CTC clusters are highly heterogeneous with
cytokeratin (CK) positive staining variations in shape, size and degree of expression. Representative
images from three patient samples are illustrated in Figure 1A. CTC-clusters were composed of two or
more individual CTCs containing distinct nuclei bound together, and with intact cytoplasmmembranes
that distinguish the background staining from leukocyte marker CD45 staining. Among the 30 patients,
CTCs were detected in 20 (66.7%) patients with a range from 1 to 347, and eight (26.7%) patients had at
least one identified CTC clusters (≥2 CTCs) with a range from 1 to 10 (Table 1). CTCs represent very
heterogeneous populations of tumorigenic cancer cells in MBC patient and some subpopulations had
undergone EMT, which expressed decreased level or absence of epithelial markers including EpCAM.
In order to characterize EMT phenotype on the captured CTCs, the immunostaining was performed
with anti-Vimentin or N-Cadherin antibodies. EMT CTCs were identified as positive staining for
Vimentin-Fluorescein isothiocyanate (FITC) or N-Cadherin-FITC, the representative images are shown
in Figure 1B. In 28 processed patient samples, 13 (46.4%) patients had at least one detected positive
either Vimentin or N-Cadherin positive CTCs (Table 1). Recent studies showed that CAMLs were
found in blood of cancer patient and their presence was associated with the stage of disease as
a blood based biomarker [14]. In this study, we detected CAMLs in MBC patient blood samples
using May-Grunwald Giemsa (MGG) combined to immunofluorescence staining (Figure 1C). Like
the CTCs, CAMLs are morphological heterogeneous in size ranges, shape, nuclear profiles. CAMLs
express diffused cytoplasmic cytokeratin and CD45-positive signals. The results were consistent with
previous observation [14], in which CAMLs express myeloid lineage (CD14+/CD11c+), CD45+, and
both cytokeratin and EpCAM epithelial markers. Among the tested 20 patient samples, 15 (75%)
patients had at least one detected CAMLs by either MGG or immunofluorescence staining (Table 1).
Together, our results demonstrated that circulating tumor associated cells can be efficiently captured
and enriched by the size-exclusion method for the cytological analysis, and a comprehensive test
including multiple markers in one blood draw is necessary to explore the heterogeneity.
Table 1. Summary of CTCs, CTC-clusters, EMT CTCs, and CAMLs detected in MBC patients.
Circulating Tumor Associated Cells Total Patients (N) Positive Patients (%)
CTCs ≥ 1 30 20 (66.7)
CTC clusters ≥ 2 CTCs 30 8 (26.7)
EMT CTCs ≥ 1 28 13 (46.4)
CAMLs ≥ 1 20 15 (75.0)
MBC, metastatic breast cancer; CTCs, circulating tumor cells; CTC clusters, circulating tumor cell clusters; EMT,
Epithelial–mesenchymal transition; CAMLs, cancer associated macrophage-like cells.
2.2. Enrichment, Single-Cell Sorting and Genome Amplification of Circulating Tumor Cells (CTCs)
To achieve the molecular characterization of the pure CTCs, a combined procedure is needed.
The proposed workflow included several steps of CTC enrichment, single-cell sorting, and whole
genome amplification (WGA) for sequencing is outlined in the Materials and Methods (Figure 2).
One MBC patient sample SKM00447 was processed for the combined procedure. CTC enrichment from
3 mL of blood was first performed using ScreenCell® Cyto devices followed by immunofluorescence
staining using anti-CK, DAPI and anti-CD45 antibodies. Forty-six CTCs/3 mL of blood were identified
with one additional device and immunostained CTCs. Ten single CTCs and four single WBCs with
good images were identified and isolated on DEPArray™ system (Figure 3A). Single CTCs and pools
of CTCs (two or three cells) were subjected to the WGA using Ampli1 WGA kit. Genome integrity was
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confirmed by PCR with the presence of short, medium, and long DNA fragments. Representative gel
image from DNA amplification in some CTCs is shown in Figure 3B.
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Figure 1. Detection of circulating cancer associated cells in metastatic breast cancer (MBC):
(A) Representative immunostaining images from three patient samples with identifications (N-S-001-87,
M-V-002-129, P-I-005-44) showing circulating tumor cells (CTCs) and CTC clusters with cytokeratin (CK)
and 4￿,6-diamidino-2-phenylindole (DAPI) positive and CD45 negative staining; (B) Immunostaining
of epithelial–mesenchymal transition (EMT) CTCs showed mesenchymal markers Vimentin or
N-Cadherin positive; (C) Representative images of cancer associated macrophage-like cells (CA Ls)
from MGG (May-Grunwald Giemsa) and immunostaining, cytological phenotypes as: spindle-shaped
(a,d); round (b,e); oblong (c); cytokeratin positive (f); CD45 positive (g); DAPI (h); and composite
image of CK and DAPI (i). The images were acquired on microscope at 40×magnification.
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Figure 2. Overall processing workflow of blood sample on: ScreenCell® Cyto device (A);
and DEPArray™ platform (B). Step 1: 3 mL of blood was processed; Step 2: Cell suspension was
recovered from the IS and transferred into 1.5 mL of Lo-bind eppendorf tube; Step 3: Enriched cells
were stained by a manual staining procedure; Step 4: Cells were resuspended in a final volume of
14 µL and loaded in a DEPArray cartridge; Step 5: Sorting procedures were performed and single cells
or pools of cells were isolated on DEPArray™ platform; Step 6: Isolated cells were subjected to WGA
using the Ampli1 WGA kit and mutation analysis.
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Figure 3. Genomic characterization of isolated CTCs. (A) Composite images visualized on the
DEPArray™ platform after ScreenCell Cyto enrichment showing single CTCs (CK-PE+/DAPI+) and
WBCs (CD45-APC+/DAPI+); (B) Gel images of Ampli1 quality control ( C) PC products from CTCs
and WBC showing the genome integrity with the presence of short, medium and long DNA fragments;
(C) The TP53 exon 6 R248W mutations were detected in single CTCs and pools of CTCs, wild-type
sequences in single WBC; (D) Wild-type ESR1 sequences were detected in all isolated CTCs.
2.3. Mutation Analysis of TP53 and ESR1 in Isolated CTCs
The patient SKM00447 was metastatic inflammatory breast cancer with estrogen receptor
(E )-positive, progesterone receptor (P )-negative, and HER2/neu-negative treated with multiple
lines of systemic therapy, including endocrine therapy and combination chemotherapy. The mutation
analysis of tumor tissue sample using commercially available NGS testing (FoundatioOne®,
Foundation Medicine, Cambridge, MA, USA) showed that the tumor harbored TP53 exon 6 248W
missense point mutation. Based on these clinical information, we analyzed single and pooled CTCs
on the mutation status of TP53 and ESR1, which is activating estrogen receptor1 and its mutation
was associated with the resistance to endocrine therapy [25]. Interestingly, heterozygous TP53 exon 6
R248Wmutation was detected in one single CTC and pools of three CTCs, and homozygous TP53 exon
6 R248W mutation was found in one single CTC and pools of two CTCs; one single WBC as control
displayed thewild-type TP53 sequence in exon 6 R248 (Figure 3C). The results suggest the heterogeneity
of TP53 mutations within the CTCs isolated even from same patient sample, and mutation profile
of CTCs was consistent with the corresponding patient￿s tumor tissue. In the same isolated CTCs,
the most common mutations in exon 8 (c.1607-1621) of ESR1 were not detected, the results showed
same wild-type ESR1 sequence from all CTCs (Figure 3D). ESR1mutation was also not found in this
patient￿s primary tumor test.
Overall, we demonstrated the applicable workflow using size-exclusion approach to enrich CTCs
for pure CTC sorting on DEPArray™ platform and further molecular characterization analysis.
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3. Discussion
CTC enumeration demonstrated a significant prognostic value, and additional blood based
markers may also play roles in furthering prognostic and predictive values in MBC. Molecular
characterization of CTCs can help determine the efficacy of selected therapeutic targets. In this
pilot study, we isolated and analyzed multiple circulating tumor associated cells including CTCs,
CTC clusters, EMTCTCs, and CAMLs by combining size-exclusion enrichment and cytological analysis
in MBC patients. The CTCs can be efficiently enriched by size-exclusion method for further use in
pure single-cells sorting on DEPArray™ platform. Mutational analysis of the isolated CTCs revealed a
heterogeneous TP53mutation in one MBC patient.
The CellSearch™ system is the only CTC enumeration platform FDA-cleared and used in the
clinical management of metastatic patients. Unfavorable prognostic outcome was determined based
on a cut-off of ≥5 CTCs per 7.5 mL of blood in MBC [7–10]. However, there are no additional further
prognostic markers in patients with ≥5 CTCs. Recent studies by our group and others have shown
that the presence of CTC clusters when CTCs were enumerated at the same analyzing time on the
CellSearch system might provide additional prognostic values over CTC enumeration alone for MBC
patients [26–28]. The CTC clusters have shown much higher metastatic potential than single CTCs
in breast cancer [27]. There is increasing evidence suggesting that EMT is involved in the metastatic
process and drug resistance in breast cancer [29]. Clinical studies shown that EMT markers were
detected in CTCs from early andmetastatic breast cancer patients [13,30,31]. Despite these observations,
very few studies have been able to demonstrate the independent prognostic value of EMT CTCs in
MBC [32,33]. Currently, there are no standard reference markers and approved methods for the
selection and detection of EMT CTCs. EpCAM-based assay is unable to capture EMT CTCs due to
the loss of epithelial features in those cells, but CTCs expressing EMT and epithelial markers can be
detected in breast cancer patients using the size-exclusion enrichment method [30,31]. Our results
showed that all CTCs, CTC clusters and EMT CTCs can be detected and identified in the peripheral
blood of MBC patients using the size-exclusion method. Additional studies in a larger number of
patients are required to validate more EMT markers and the prognostic value in MBC.
Another potential blood-based biomarker for solid tumors are CAMLs. Recent studies have
shown that the presence of CAMLs may be associated with malignant diseases and activation of
innate immunity in cancer patients [14,34]. The detection of CAMLs may differentiate malignant
disease and benign breast lesions as described in a recent report [35]. However, the function and
prognostic value of CAMLs and the role in activation of innate immunity in cancer patients remain
unknown. Consistent with previous findings, CAMLs were detected in 15 (75%) patients among
20 MBC patients and showed a considerable heterogeneity in the phenotypes. Given the larger size of
CAMLs, size-exclusion methods may offer a significant advantage for capturing these cells. Further
molecular and functional validation of CAMLs in larger numbers of patients will open a path to
comprehensive blood-based biomarker access.
A recent clinical trial showed that CTC enumeration alone was not sufficient to guide
chemotherapeutic treatment change for survival benefits in MBC [36], which highlights the importance
of CTC molecular characterization to be more informative for the choice of treatment options.
Monitoring CTC characterization over a period of time seems necessary since marker profiles can
change during the course of therapy and disease progression. For the first time, we tested the feasibility
that CTCs were enriched using the size-exclusion method and followed by DEPArray™ isolation to
achieve mutation analysis on the single cell or pools of CTCs in oneMBC patient sample. CTCs showed
the matched TP53 R248W mutation with the patient￿s tissue tumor although a heterogeneity within
CTCs. The results from one recent study showed the extreme heterogeneity of the mutational status of
single CTCs in metastatic breast cancer patients [23], there is also a discordance between the mutational
status of the primary tumor and CTCs among three analyzed patients. Enriched CTCs using the
CellSearch method followed by DEPArray™ sorting for the molecular profiling of single CTCs has
been recently reported [22–24]. Here, we present the size-exclusion method with high efficacy, low-cost,
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and flexibility to enrich CTCs. The method has a potential advantage for EMT CTCs and CAMLs
enrichment to achieve the molecular profiling analysis in single cells or pure population of cells by
combining DEPArray™ technology.
In summary, our data suggest that blood-based method using multiple markers analysis and
molecular characterization of CTCs can be achieved by a combined method. Along with the further
evaluation of association with patient outcomes, more studies with larger sample size and longer
follow-up are warranted to confirm these findings and explore their clinical value. The comprehensive
analysis from one blood draw as a non-invasive approach holds promise in clinical applicability for
future personalize treatment of MBC patients.
4. Materials and Methods
4.1. Study Patients
Female MBC (stage IV) patients were identified from a clinic-based cohort of breast cancer patients
who visited the Breast Care Center at the Sidney Kimmel Cancer Center at Thomas Jefferson University
Hospital (Philadelphia, PA, USA). MBC diagnosis was based on tissue histology, complemented by
radiological evaluations. This study was approved by the Office of Human Research, Division of
Human Subjects Protection, Institutional Review Board (IRB) of Thomas Jefferson University Hospital
(October 2013, protocol #13P.302). Written informed consent was obtained from all patients before
blood samples were collected.
4.2. Blood Sample Collection and Processing
Approximately 8 mL of whole blood was collected in K2EDTA vacutainers or Transfix tubes
and kept at room temperature. All samples were processed within 4 h (K2EDTA tubes) or 72 h
(Transfix tubes) of being drawn. CTCs were captured on the isolation support (IS) using size-exclusion
Cyto devices according to the manufacturer￿s instruction (ScreenCell, Sarcelles, France) as previously
described [16]. The ScreenCell® device is holding an IS with 18-µm-thick polycarbonate membrane
with circular pores (6.5 ± 0.33 µm) that are randomly distributed throughout membrane and a
detachable nozzle attached to it. This nozzle guides the insertion of a collection tube to it to gently
vacuum the blood through the IS, leaving the CTCs on the IS. The process is quick (3 min) [16].
Briefly, 3 mL of blood was mixed with 4 mL of ScreenCell® FC2 dilution buffer and incubated for
8 min at room temperature. After incubation, diluted blood was passed through the ScreenCell Cyto
device by vacuum force, and IS was rinsed by adding 1.6 mL of Phosphate Buffered Saline (PBS).
After the enrichment, the IS was disassembled from the ScreenCell device, and allowed to air dry.
The dried IS was stored at 4 or −20 ◦C until further cytological analysis. Two ISs were collected for
each patient sample.
4.3. Cytological Analysis
For cytological evaluation, the IS was rehydrated with Tris-buffered saline (TBS) and subjected
to standard MGG (May-Grunwald Giemsa) staining with May Grunwald dye and Giemsa (EMD
Millipore, Billerica, MA, USA). Stained IS was evaluated based on the cytomorphological features
under light microscope. MGG stained IS can be reused for further immunofluorescence staining
after removing MGG staining by washing the IS with TBS containing 0.05% Tween 20 (TBST) for
20 min at room temperature (RT). Identification of CTCs and CTC clusters were determined based on
the immunofluorescence staining of phycoerythrin (PE)-conjugated cytokeratins (CK-8, 18 and 19),
DAPI (4￿,6-diamidino-2-phenylindole) (CellSearch® CTC kits, Janssen Diagnostics), and CD45-FITC
antibodies (clone HI30, Biolegend, San Diego, CA, USA). In brief, the IS was rehydrated with TBS
and permeabilized with TBS containing 0.2% Triton X-100. After blocking with 3% BSA (bovine
serum albumin) for 30 min, the IS was stained with CK-PE and CD45-FITC for 45 min, and then
DAPI for 5 min at RT. For EMT CTCs identification, the IS was stained with Vimentin-FITC (Santa
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Cruz Biotechnology, Santa Cruz, CA, USA) and N-Cadherin (eBioscience, San Diego, CA, USA)
followed by Alexa Fluor 647 donkey anti-mouse antibody. The stained IS was viewed and images
of stained cells were captured on Olympus BX43 Fluorescence Digital Imaging System or NIKON
Eclipse 80i microscope. Positive CTCs were identified based on staining for both CK and DAPI
positive, and for CD45 negative (CK+/DAPI+/CD45−). CTC clusters showed as a group of two
or more individual CTCs containing distinct nuclei and intact cytoplasm membranes as previously
described [26]. EMT positive CTCs were identified by positive staining for Vimentin or N-Cadherin
and DAPI, and negative staining for CD45 (Vimentin+ or N-Cadherin+/DAPI+/CD45−). CAMLs were
identified by MGG or immunofluorescence staining by CK-FITC.
4.4. CTCs Enrichment and Single-Cell Sorting by DEPArray™ System
CTCs were first enriched using ScreenCell Cyto devices and then sorted on DEPArray™ (Silicon
Biosystems) system for collecting single CTCs or pools of CTCs. The overall experimental workflow is
illustrated in Figure 2. CTCs enrichment was performed as described above and the single-cell sorting
was conducted according to the manufacturer￿s instruction for DEPArray™ analysis. Briefly, diluted
blood (3 mL of blood mixed with 4 mL of FC2 dilution buffer) was passed through the hydrated IS of
ScreenCell Cyto device with loading Buffer (PBS containing 3% BSA and 5 mM EDTA). The IS was
covered with a drop of loading buffer after cell enrichment and was released from the device onto
the pertri dish containing parafilm foil. The cells on the IS were detached by pipetting the liquid for
several times and transferred into 1.5 mL of Lo-bind eppendorf tube. The recovering process was
repeated by adding the loading buffer as necessary. The cells were centrifuged at 400× g for 10 min
at RT and the supernatant was carefully removed. The cell pellets were reconstituted in TBS and
proceeded to immunofluorescence staining by CK-PE, CD45-APC and DAPI (CellSearch® CTC kits,
Janssen Diagnostics). Enriched CTCs were then sorted on DEPArray™ platform (Figure 2). In brief,
both 800 µL of SB115 buffer (Silicon Biosystems) and 14 µL of sample in SB115 buffer were loaded
on the DEPArray™ cartridge chip (DEPArray™ A300K-cartridge, Silicon Biosystems). The chip was
scanned in first step, and images of cells were captured and processed for selecting CTCs and WBCs
based on CK-PE/DAPI positive staining for CTCs or CD45-APC/DAPI positive staining for WBCs as
control. At final step, single CTCs or pools of CTCs, and single WBCs as control were recovered into
individual 200 µL of PCR tubes. The samples were centrifuged at 14,000× g for 10 min and washed
once with 100 µL of PBS. The buffer was removed from the tube and the cell pellets in 1–2 µL volume
were proceeded to whole genome amplification (WGA) or stored at 80 ◦C until further WGA.
4.5. Ampli1™ Whole Genome Amplification and Quality Control Assays
The Ampli1™WGA procedure is based on a ligation-mediated PCR following a site-specific DNA
digestion with a library of highly concentrated DNA, which can be employed for further targeted
genetic analysis. The DNA from the isolated CTCs or WBCs was amplified using the Ampli1™ kit
WGA (Silicon Biosystems) according to the manufacturer￿s instruction. Briefly, the isolated CTCs were
thawed on ice and brought up to a volume of 1 µL of PBS to perform all the reaction in same tube
as following steps: cell lysis, DNA digestion, ligation, and primary PCR according to the procedure
of the supplier resulting in final volume 50 µL of WGA product. Genome integrity was evaluated
using the Ampli 1-QC kit (Silicon Biosystems, Inc). Ampli 1-QC kit is a PCR assay which allows the
simultaneous amplification of four different human genomic targets using 1 µL of an Ampli1™WGA
product. PCR products were visualized on a 1.5% agarose gel to determinate the genome integrity as
previously described [22].
4.6. TP53 and ESR1 Mutations in CTCs
Amplified DNA from CTCs was used for TP53 and ESR1 mutations analysis which was
performed by Sanger sequencing. The primers reverse 5￿-GAAATCGGTAAGAGGTGGGC-3￿
and forward 5￿-GCTTGCCACAGGTCTCCCCA-3￿ were used to amplify hot spot region in
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exon 6 of TP53 (R248). The primers reverse 5￿-CCCCAACCCATAGACTGAG-3￿ and forward
5￿-GCTAAGTGCTTTGGAGTTC-3￿ were used to amplify the exon 8 of ESR1 (K531E, V534E, P535H,
L536R/Q, Y537N/C/S, D538G). PCR reactions were performed using the AmpliTaq-Gold Taq DNA
polymerase (Applied Biosystems, Foster City, CA, USA) according to manufacturer￿s instructions.
Both genes were amplified at 95 ◦C for 30 s as the denaturation, at 60 ◦C for TP53 and 57 ◦C for
ESR1 for 30 s as the annealing, and at 72 ◦C for 30 s as the primer extension for a total of 30 cycles.
The amplified products were separated by electrophoresis on a 2% agarose/1× TAE (Tris, acetic acid,
EDTA) gel. The PCR products were cleaned using the Amicon Microcon PCR purification kit (EMD
Millipore, Billerica, MA, USA). The purified PCR product were finally sequenced on the ABI PRISM®
3700 (Applied Biosystems) capillary genetic analyzer with the same primers in both directions.
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